Literature DB >> 27981691

The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California.

Emanuel Krebs1, Darren Urada2, Elizabeth Evans2, David Huang2, Yih-Ing Hser2, Bohdan Nosyk1,2,3.   

Abstract

BACKGROUND AND AIMS: Treatment for opioid use disorders (OUD) reduces the risk of mortality and infectious disease transmission; however, opportunities to quantify the potential economic benefits of associated decreases in drug-related crime are scarce. This paper aimed to estimate the costs of crime during and after periods of engagement in publicly funded treatment for OUD to compare total costs of crime during a hypothetical 6-month period following initiation of opioid agonist treatment (OAT) versus detoxification.
DESIGN: Retrospective, administrative data-based cohort study with comprehensive information on drug treatment and criminal justice systems interactions.
SETTING: Publicly funded drug treatment facilities in California, USA (2006-10). PARTICIPANTS: A total of 31 659 individuals admitted for the first time to treatment for OUD, and who were linked with criminal justice and mortality data, were followed during a median 2.3 years. Median age at first treatment admission was 32, 35.8% were women and 37.1% primarily used prescription opioids. MEASUREMENTS: Daily costs of crime (US$2014) were calculated from a societal perspective and were composed of the costs of policing, court, corrections and criminal victimization. We estimated the average marginal effect of treatment engagement in OAT or detoxification adjusting for potential fixed and time-varying confounders, including drug use and criminal justice system involvement prior to treatment initiation.
FINDINGS: Daily costs of crime during treatment compared with after treatment were $126 lower for OAT [95% confidence interval (CI) = $116, $136] and $144 lower for detoxification (95% CI = $135, $154). Summing the costs of crime during and after treatment over a hypothetical 6-month period using the observed median durations of OAT (161 days) and detoxification (19 days), we estimated that enrolling an individual in OAT as opposed to detoxification would save $17 550 ($16 840, $18 383).
CONCLUSIONS: In publicly funded drug treatment facilities in California, USA, engagement in treatment for opioid use disorders is associated with lower costs of crime in the 6 months following initiation of treatment, and the economic benefits were far greater for individuals receiving time-unlimited treatment.
© 2016 Society for the Study of Addiction.

Entities:  

Keywords:  California; costs of crime; heroin; opioid agonist treatment; opioid use disorder; prescription opioids

Mesh:

Year:  2017        PMID: 27981691      PMCID: PMC5382102          DOI: 10.1111/add.13729

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  56 in total

1.  Estimating log models: to transform or not to transform?

Authors:  W G Manning; J Mullahy
Journal:  J Health Econ       Date:  2001-07       Impact factor: 3.883

2.  Cross-system data linkage for treatment outcome evaluation: lessons learned from the California Treatment Outcome Project.

Authors:  Yih-Ing Hser; Elizabeth Evans
Journal:  Eval Program Plann       Date:  2008-02-19

3.  Drug use and crime: a historical review of research conducted by the UCLA Drug Abuse Research Center.

Authors:  M D Anglin; B Perrochet
Journal:  Subst Use Misuse       Date:  1998-07       Impact factor: 2.164

4.  Characterizing durations of heroin abstinence in the California Civil Addict Program: results from a 33-year observational cohort study.

Authors:  Bohdan Nosyk; M Douglas Anglin; Mary-Lynn Brecht; Viviane Dias Lima; Yih-Ing Hser
Journal:  Am J Epidemiol       Date:  2013-02-27       Impact factor: 4.897

5.  Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs.

Authors:  Christina M Andrews; Thomas A D'Aunno; Harold A Pollack; Peter D Friedmann
Journal:  Med Care Res Rev       Date:  2013-09-18       Impact factor: 3.929

6.  Observed transition from opioid analgesic deaths toward heroin.

Authors:  Nabarun Dasgupta; Kathleen Creppage; Anna Austin; Christopher Ringwalt; Catherine Sanford; Scott K Proescholdbell
Journal:  Drug Alcohol Depend       Date:  2014-10-18       Impact factor: 4.492

7.  Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment.

Authors:  Bohdan Nosyk; Daphne P Guh; Nicholas J Bansback; Eugenia Oviedo-Joekes; Suzanne Brissette; David C Marsh; Evan Meikleham; Martin T Schechter; Aslam H Anis
Journal:  CMAJ       Date:  2012-03-12       Impact factor: 8.262

8.  Lifetime history of heroin use is associated with greater drug severity among prescription opioid abusers.

Authors:  Andrew C Meyer; Mollie E Miller; Stacey C Sigmon
Journal:  Addict Behav       Date:  2014-11-18       Impact factor: 3.913

Review 9.  Economic Evaluations of Opioid Use Disorder Interventions.

Authors:  Sean M Murphy; Daniel Polsky
Journal:  Pharmacoeconomics       Date:  2016-09       Impact factor: 4.981

10.  A day-by-day investigation of changes in criminal convictions before and after entering and leaving opioid maintenance treatment: a national cohort study.

Authors:  Anne Bukten; Jo Røislien; Svetlana Skurtveit; Helge Waal; Michael Gossop; Thomas Clausen
Journal:  BMC Psychiatry       Date:  2013-10-16       Impact factor: 3.630

View more
  14 in total

1.  Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population.

Authors:  Elizabeth R Stevens; Kimberly A Nucifora; Holly Hagan; Ashly E Jordan; Jennifer Uyei; Bilal Khan; Kirk Dombrowski; Don des Jarlais; R Scott Braithwaite
Journal:  Clin Infect Dis       Date:  2020-06-10       Impact factor: 9.079

2.  The costs of crime associated with stimulant use in a Canadian setting.

Authors:  Benjamin Enns; Emanuel Krebs; Kora DeBeck; Kanna Hayashi; M-J Milloy; Lindsey Richardson; Evan Wood; Bohdan Nosyk
Journal:  Drug Alcohol Depend       Date:  2017-09-14       Impact factor: 4.492

3.  Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities.

Authors:  Ramin Mojtabai; Christine Mauro; Melanie M Wall; Colleen L Barry; Mark Olfson
Journal:  Health Aff (Millwood)       Date:  2019-01       Impact factor: 6.301

4.  Estimating State Transitions for Opioid Use Disorders.

Authors:  Emanuel Krebs; Jeong E Min; Elizabeth Evans; Libo Li; Lei Liu; David Huang; Darren Urada; Thomas Kerr; Yih-Ing Hser; Bohdan Nosyk
Journal:  Med Decis Making       Date:  2016-12-27       Impact factor: 2.583

Review 5.  The American Opioid Epidemic in Special Populations: Five Examples.

Authors:  Carlos Blanco; Mir M Ali; Aaron Beswick; Karen Drexler; Cheri Hoffman; Christopher M Jones; Tisha R A Wiley; Allan Coukell
Journal:  NAM Perspect       Date:  2020-10-26

6.  Patient Pain Experiences and the Emergency Department Encounter: A Qualitative Analysis.

Authors:  Brittany E Punches; Jennifer L Brown; Summer Soliman; Kimberly D Johnson; Caroline E Freiermuth; Quinn Walker; Shammah O Omololu; Michael S Lyons
Journal:  Pain Manag Nurs       Date:  2022-05-01       Impact factor: 2.356

7.  Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder.

Authors:  Elizabeth A Evans; Donna Wilson; Peter D Friedmann
Journal:  Drug Alcohol Depend       Date:  2022-01-18       Impact factor: 4.492

8.  Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review.

Authors:  Erica N Onuoha; Jared A Leff; Bruce R Schackman; Kathryn E McCollister; Daniel Polsky; Sean M Murphy
Journal:  Value Health       Date:  2021-05-08       Impact factor: 5.101

9.  Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice.

Authors:  Mark Deyo-Svendsen; Matthew Cabrera Svendsen; James Walker; Andrea Hodges; Rachel Oldfather; Meghna P Mansukhani
Journal:  J Prim Care Community Health       Date:  2020 Jan-Dec

10.  How simulation modeling can support the public health response to the opioid crisis in North America: Setting priorities and assessing value.

Authors: 
Journal:  Int J Drug Policy       Date:  2020-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.